Editorial · 29 Oct 2026
Conference abstractPublished 30 Aug 2023
Treatment outcomes with tocilizumab in adult patients with severe and critical COVID-19 pneumonia of mariano marcos memorial hospital and medical center: A Retrospective Study
Mariano Marcos Memorial Hospital & Medical Center, Philippines
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objectives: As SARS-Cov-2 infection leads to the development of cytokine storm syndrome, Tocilizumab, a biological agent that inhibits the cytokine interleukin 6, was seen to have clinical effects in COVID-19. Hematological markers used to determine clinical severity based on current literature revealed that ALC, CRP, Ferritin, LDH and D-dimer levels were associated with COVID severity. We aimed to determine the association of recovery and mortality rate with Tocilizumab based on inflammatory markers significant in COVID-19 infection such as CRP, LDH, D-dimer, Ferritin, Absolute Lymphocyte Count and associate comorbidities of patients to mortality. Methods: This was a single-center retrospective study which includes 101 t patients diagnosed with COVID-19 Severe and Critical Pneumonia. Independent Sample T-test, Mann-Whitney U test and FisherâÂ?Â?s Exact/Chi-square test was used. Odds ratio was computed to determine significant predictors for mortality. Results: Diabetic patients were 5.3 times more likely to and Chronic Kidney Disease was 18 times more likely to have mortality. For every unit increase in patientâÂ?Â?s D-dimer and CRP during admission, the odds of mortality also increase by 0.02% and 0.73%, 0.01, unit decrease in patientâÂ?Â?s Absolute 0.02,w Lymphocyte Count during admission, the odds of Mortality decrease by 17.86%. Every 0.01-unit increase in patientâÂ?Â?s ABG PaO2/FiO2 during admission, the odds of mortality decrease by 10.1%. In patientâÂ?Â?s D-dimer, Ferritin, CRP and LDH prior to discharge, every unit increase, the odds of mortality also increase by 0.03%, 0.18%, 2.29% and 0.58, respectively. Every 0.01-unit increase in patientâÂ?Â?s ALC prior discharge, mortality decrease by 13.35%. Conclusion: Tocilizumab treatment was associated with reduction in the mortality of patient with Severe and Critical COVID Pneumonia in association with inflammatory markers, LDH, Ferritin, D-dimer and CRP, improvement of ABG PaO2/FIO2 and decreased infiltrates by chest x-ray. Mortality from COVID-19 Pneumonia was associated with CKD, DMT2, and HCVD Recent Publications Manalo, G., Lu-Reyes, J., Carabbacan C., Santos, M., Pascual, S. Therapeutic Plasma Exchange as a Treatment for Central Pontine Myelinolysis in a 41 year old Male with Chronic Renal Insufficiency: A Case Report; Philippine Journal of Internal Medicine (Volume 60 No. 4)
Subjects
Alternative & Palliative CareAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Palliative Care & Medicine.
Research article · 9 Feb 2026
Emerging Needs of Psycho-Oncologist in Indian Clinical Practices
Perspective · 14 Jan 2026
Creating an Advance Directive: A Step-by-Step Approach
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Palliative Care & Medicine
- SubjectAlternative & Palliative Care
- BylineArticles whose byline prints “Sheryll J. Pascual”